Systemic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease

Health Technology Assessment

Volumn 7, Issue 3, 2003, Pages

  Clark, W ^a   Raftery, J ^b   Song, F ^b   Barton, P ^b   Cummins, C ^c   Fry Smith, A ^b   Burls, A ^b  

^a KEELE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c Insti tute of Child Health   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; ANTIBIOTIC AGENT; AZATHIOPRINE; BUDESONIDE; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; SALAZOSULFAPYRIDINE; TACROLIMUS; TUMOR NECROSIS FACTOR ANTIBODY;

ARTHRITIS; CLINICAL FEATURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DISEASE ACTIVITY; DISEASE SEVERITY; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG TOXICITY; ECONOMIC EVALUATION; FASCIITIS; FISTULA; GASTROINTESTINAL SURGERY; HUMAN; MAINTENANCE THERAPY; PNEUMONIA; PREVALENCE; PROGNOSIS; QUALITY OF LIFE; REMISSION; REVIEW;

EID: 0038030704     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn's disease activity index. Gastroenterology 1976;70:439-44.
2. Development and validation of an endoscopic index of the severity for Crohn's disease: A prospective multicentre study. Gut 1989;30:983-9.
3. Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989;96:804-10.
4. Rutgeerts P. Medical therapy of inflammatory bowel disease. Digestion 1998;59:453-69.
5. Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, Groll A, et al. Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology 1994;106:287-96.
6. Irvine EJ. Usual therapy improves perianal Crohn's disease as measured by a new Disease Activity Index. J Clin Gastroenterol 1995;20:27-32.
7. Jewell D. Crohn's disease. Medicine 1998;26:87-92.
8. British Society of Gastroenterology Clinical Guidelines. Inflammatory bowel disease. 1996 Available from: http://www.bsg.org.uk/pdf_word_docs/ibd.pdf
9. Sachar DB, Andrews HA, Farmer RG, Pallone F, Pena AS, Prantera C, et al. Proposed classification of patient subgroups in Crohn's disease. Gastroenterology Int 1992;5:141-54.
10. D'Haens G, Rutgeerts P. Treatment of active Crohn's disease. Res Clin Forum 2000;22:69-75.
11. Mekhjian HS, Switz DM, Melnyk CS, Rankin GB, Brooks RK. Clinical features and natural history of Crohn's disease. Gastroenterology 1979;77:898-906.
12. Sartor RB. New therapeutic approaches to Crohn's disease. N Engl J Med 2000;342:1664-6.
13. Farmer RG, Whelan G, Fazio VW. Long-term follow-up of patients with Crohn's disease. Gastroenterology 1985;88:1825.
14. Hanauer SB, Meyers S. Management of Crohn's disease in adults. Am J Gastroenterol 1997;92:559-65.
15. Hanauer SB, Cohen RD, Becker RV, Larson LR, Vreeland MG. Advances in the management of Crohn's disease: Economic and clinical potential of infliximab. Clin Ther 1998;20:1009-29.
16. Wall GC, Heyneman C, Pfanner TP. Medical options for treating Crohn's disease in adults: Focus on antitumor necrosis factor-alfa chimeric monoclonal antibody. Pharmacotherapy 1999;19:1138-52.
17. Sutherland LR, Ramcharan S, Bryant H, Fick G. Effect of cigarette smoking on recurrence of Crohn's disease. Gastroenterology 1990;98:1123-8.
18. Kaufmann HJ, Taubin HL. Non-steroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med 1987;107:513-16.
19. Logan RFA. Inflammatory bowel disease incidence: Up, down or unchanged? Gut 1998;42:309-11.
20. National Association for Colitis and Crohn's Disease. Fact sheet on inflammatory bowel disease. 2000. Available from: http://www.nacc.org.uk
21. Munkholm P, Langholtz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995;30:699-706.
22. Andersson P, Olaison G, Bodemar G, Almer S, Arvidsson M, Dabrosin-Soderholm J, et al. Low symptomatic load in Crohn's disease with surgery and medicine as complementary treatments. Scand J Gastroenterol 1998;33:423-9.
23. Silverstein MD, Loftus EV, Sandborn WJ, Tremaine WJ, Feagan BG, Nietert PJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 1999;117:49-57.
24. Gregor J, McDonald JWD, Klar N, Wall R, Atkinson K, Lamba B, et al. An evaluation of utility measurement in Crohn's disease. Inflamm Bowel Dis 1997;3:265-276.
25. Summers RW, Switz DM, Sessions JTJ, Becktel JM, Best WR, Kern J Jr, et al. National Cooperative Crohn's Disease Study: Results of drug treatment. Gastroenterology 1979;77:847-69.
26. Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, et al. European Cooperative Crohn's disease study (ECCDS): Results of drug treatment. Gastroenterology 1984;86:249-66.
27. Salomon P, Kornbluth A, Aisenberg J, Janowitz HD. How effective are current drugs for Crohn's disease? J Clin Gastroenterol 1992;14:211-15.
28. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Successful management of Crohn's disease of the ileonal pouch with infliximab. Gastroenterology 1999;117:429-32.
29. Lang KA, Peppercorn MA. Promising new agents for the treatment of inflammatory bowel disorders. Drugs Res Dev 1999;1:237-44.
30. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994;35:360-2.
31. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C, et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. In: The Cochrane Library. Issue 1. Oxford: Update Software; 2000.
32. Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, et al. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995;332:292-7.
33. Lowry PW, Sandborn WJ, Lipsky JJ. Mycophenolate mofetil for Crohn's disease? Lancet 1999;354:3-4.
34. Rutgeerts P, Baert F. New strategies in the management of inflammatory bowel disease. Acta Clin Belg 1999;54:274-80.
35. Sandborn WJ. Therapy for Crohn's disease. Curr Opin Gastroenterol 2000;16:318-23.
36. Lichtenstein GR. Treatment of fistulizing Crohn's disease. Gastroenterology 2000;119:1132-47.
37. Messori A, Brignola C, Trallori G, Rampazzo R, Bardazzi G, Belloli C, et al. Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: A meta-analysis. Am J Gastroenterol 1994;89:692-8.
38. Steinhart AH, Hemphill D, Greenberg GR. Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: A meta-analysis. Am J Gastroenterol 1994;89:2116-24.
39. Camma C, Giunta M, Rosseli M, Cottone M. Mesalamine in the maintenance treatment of Crohn's disease: A meta-analysis adjusted for confounding variables. Gastroenterology 1997;113:1465-73.
40. Steinhart AH, Ewe K, Griffiths AM, Modigliani R, Thomsen OO. Corticosteroids for maintaining remission of Crohn's disease. In: The Cochrane Library. Issue 1. Oxford: Update Software; 2000.
41. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. In: The Cochrane Library. Issue 1. Oxford: Update Software; 2000.
42. Modigliani R. Immunosuppressors for inflammatory bowel disease: How long is long enough? Inflamm Bowel Dis 2000;6:251-7.
43. Hanauer SB. Medical therapy for Crohn's disease. Curr Opin Gastroenterol 1999;15:308-14.
44. Onrust SV, Lamb HM. Infliximab: A review of its use in Crohn's disease and rheumatoid arthritis. BioDrugs 1998;10:397-422.
45. Van Hogezand RA, Verspaget HW. The future role of anti-tumour necrosis factor-alfa products in the treatment of Crohn's disease. Drugs 1998;56:299-305.
46. Committee for Proprietary Medicinal Products. Remicade. European Public Assessment Report (EPAR), 1999. Report No. CPMP/1901/99. Available from: http://www.eudra.org/humandocs/Human/EPAR/Remicade/Remica de.htm
47. Remicade 100 mg Powder for Concentrate for Solution for Infusion. Summary of Product Characteristics. Leiden, The Netherlands: Centocor BV; 1999.
48. Bell SJ, Kamm MA. Review article: The clinical role of anti-TNF-alfa antibody treatment in Crohn's disease. Aliment Pharmacol Ther 2001;14:501-14.
49. Remicade: Lyophilized Concentrate for IV Infusion. Product Monograph. Leiden, The Netherlands: Centocor BV: 2000.
50. Department of Public Health and Epidemiology. West Midlands Development and Evaluation Service (DES) Handbook. Report No. 8 2.2:1-142. Birmingham: DPHE; 1999.
51. NHS Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness. CRD's Guidelines for Those Carrying Out or Commissioning Reviews. CRD Report Number 4 (2nd ed.). York: University of York; 2001.
52. Remicade for Crohn's Disease. Clinical trial information. 2000. URL: http://www.remicade-crohns.com/hcp/clinical.html
53. Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, et al. Tumor necrosis factor alfa antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999;116:22-8.
54. D'Haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, et al. Endoscopic and histological healing with infliximab anti-tumour necrosis factor antibodies in Chrohn's disease. Gastroenterology 1999;116:1029-34.
55. Derkx B, Taminiau J, Tadema S, Stonkhorst A, Wortel C, Tytgart G, et al. Tumour-necrosis-factor antibody treatment in Crohn's disease. Lancet 1993;342:173-4.
56. Heller T, James SP, Drachenberg C, Hernandez C, Darwin PE. Treatment of severe esophageal Crohn's disease with infliximab. Inflamm Bowel Dis 1999;5:279-82.
57. Hommes DW, Van Dullemen HM, Meenan J, Van Den Ende A, Woody J, et al. The effect of monoclonal anti-tumor necrosis factor antibody cA2 on coagulation and fibrinolytic parameters in patients with active Crohn's disease [abstract]. Gastroenterology 1995;108:A838.
58. Hommes DW, Van Dullemen HM, Levi M, Van Den Ende A, Woody J, et al. The effect of monoclonal anti-tumor necrosis factor antibody cA2 on coagulation and fibrinolytic parameters in patients with active Crohn's disease. Thromb Haemost 1995;73:946.
59. Hommes DW, Van Dullemen HM, Levi M, Van Der Ende A, Woody J, Tytgat GN, et al. Beneficial effect of treatment with a monoclonal anti-tumor necrosis factor-alfa antibody on markers of coagulation and fibrinolysis in patients with Crohn's disease. Haemostasis 1997;27:269-77.
60. Kammerer W. Infliximab gegen fisteln bie morbus Crohn (In Dutch). Pharm Ztg 1999;33:(144):32.
61. McCabe RP, Woody J, Van Deventer S, Targan SR, Mayer L, et al. A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn's disease [abstract]. Gastroenterology 2000;110:A962.
62. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, Van Hogezand RA, et al. Infliximab for the treatment of fistulae in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
63. Present DH. Review article: The efficacy of infliximab in Crohn's disease - Healing of fistulae. Aliment Pharmacol Ther 1999;13 Suppl 4:23-8.
64. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, et al. Infliximab for fistulas: A hole in one? Inflamm Bowel Dis 2000;6:62-3.
65. Rasmussen SN, Petersen JA. Behandling af morbus Crohn med anti-tumornekrosis-faktor-alfa (In Danish). Ugeskr Laeger 1999;1761:4026-9.
66. Rutgeers P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9.
67. Stack WB, Mann SD, Roy AJ, Heath P, Sopwith M, Freeman J, et al. A controlled trial of anti-tumor necrosis factor alfa antibody for Crohn's disease. Gastroenterology 1997;113:1042-3.
68. Targan S, Hanauer SB, Van Deventer SJH, Mayer L, Present DH, Braakman T, et al. A short term study of chimeric monoclonal antibody cA2 to tumour necrosis factor alpha for Crohn's disease. N Engl J Med 1997;337:1029-35.
69. Van Dullemen HM, Van Deventer SJH, Hommes DW, Bijl HA, Jansen J, Tytgat GN et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129-35.
70. Van Den Bosch F, Kruithof E, De Vos M, De Keyser F, Mielants H. Crohn's disease associated with spondyloarthropathy: Effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 2000;356:1821-1.
71. Lofberg R. Treatment of fistulas in Crohn's disease with infliximab. Gut 1999;45:642-3.
72. Bourreille A. TNF-alfa et interleukine 1 beta dans les rechutes de maladie de Crohn (In French). Hepatogastroenterology 1999;3:232-3.
73. Ricart E, Sandborn WJ. Infliximab for the treatment of fistulae in patients with Crohn's disease. Gastroenterology 1999;117:1247-51.
74. Remicade (infliximab) for IV injection. Physicians Desk Reference, 2000. Accessed via: http://www.pdr.net
75. ACCENT I: A Crohn's disease clinical trial evaluating infliximab in a new long term treatment regimen. Presented at Digestive Disease Week; 2001 May 20-23; Atlanta, GA, USA.
76. Department of Health and Human Services. Statistical review: Chimeric monoclonal antibody (cA2) to tumor necrosis factor for inflammatory bowel disease (Crohn's disease). Food and Drug Administration Memorandum 1998. Rockville, MD: FDA; 1998.
77. European Agency for the Evaluation of Medicinal Products. Reports of Tuberculosis Infections. EMEA Public Statement on Infliximab (Remicade) 2000;1-8.
78. A randomized double-blind, placebo-controlled trial of anti-TNF alfa chimeric monoclonal antibody (infliximab, Remicade) in the long-term treatment of patients with moderately to severely active Crohn's disease (ACCENT I). Protocol 1998; C0168T21:1-64. Leiden, The Netherlands: Centocor BV; 1998.
79. Infliximab (T16 Trial). Application for Marketing Authorization, Part IV 1998; 27. Leiden, The Netherlands: Centocor BV; 1998.
80. Hanauer SB. Review article: Safety of infliximab in clinical trials. Aliment Pharmacol Ther 1999; 13 (Suppl 4):16-22.
81. Farrell M, Shah S, Lodhavia M, Alsahli M, Falchuck K, Michetti P, et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterology 2000;95:3490-7.
82. Infliximab (Remicade) and tuberculosis. In: CSM Current Problems & Pharmacovigilance: No 27. London: Medicines Control Agency and Committee on Safety of Medicines; 2001. p.7.
83. Menghini VV, Arora AS. Infliximab-associated reversible cholestatic liver disease. Mayo Clin Proc 2001;76:84-6.
84. Bickston SJ, Lichtenstein GR, Arseneau KOCRB, Cominelli F. The relationship between infliximab treatment and lymphoma in Crohn's disease. Gastroenterology 1999;117:1433-7.
85. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999;5:119-33.
86. Remicade in the Treatment of Crohn's Disease in the UK. Submission to the National Institute for Clinical Excellence. Welwyn Garden City, UK: Schering Plough; 29 May 2001.
87. Ullman TA. Markov Polo: Finding the costs of Crohn's in an Olmstead County pool. Inflamm Bowel Dis 2000;6:64-5.
88. Arseneau KO, Cohn SM, Cominelli F, Connors AF Jr. Cost-utility of initial medical management for Crohn's disease perianal fistulae. Gastroenterology 2001;120:1640-56.
89. Lochs H, Adler G, Beglinger CH, Duchmann R, Emmrich J, Ewe K, et al. Anti-TNF antibody in Crohn's disease - Status of information, comments and recommendations of an international working group. Z Gastroenterol 1999;37:509-12.
90. Hanauer SB, Sandborn W. Management of Crohn's disease in adults. Am J Gastroenterol 2001;96:635-43.
91. Schreiber S, Campieri M, Colombel JF, Van Deventer SJH, Feagan B, Fedorak R, et al. Use of anti-tumor necrosis factor agents in inflammatory bowel disease. European guidelines for 2001-2003. Int J Colorectal Dis 2001;16:1-11.
92. Nikolaus S, Raedler A, Kuhbacher T, Sfikas N, Folsch UR, Schreiber S. Mechanisms in failure of infliximab for Crohn's disease. Lancet 2000;356:1475-9.